Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prestige Consumer Healthcare's earnings per share without non-recurring items for the
three
months ended in Jun. 2026 was $0.61.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2026 was $3.67.
During the past 12 months, Prestige Consumer Healthcare's average earnings per share (NRI) Growth Rate was -19.90% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 1.30% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 5.40% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 6.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Prestige Consumer Healthcare's EPS without NRI or its related term are showing as below:
PBH'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -40.1 Med: 11.2 Max: 230.2
Current: 1.3
During the past 13 years, Prestige Consumer Healthcare's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 230.20% per year. The lowest was -40.10% per year. And the median was 11.20% per year.
PBH's 3-Year EPS without NRI Growth Rate is ranked worse than 61.91% of 785
companies
in the Drug Manufacturers industry
Industry Median: 9.7
vs PBH: 1.30
Prestige Consumer Healthcare (NYSE:PBH) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Prestige Consumer Healthcare EPS without NRI Related Terms
Prestige Consumer Healthcare EPS without NRI Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prestige Consumer Healthcare EPS without NRI Chart
PBH vs BCRX, AMLX, SUPN: EPS without NRI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prestige Consumer Healthcare PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Prestige Consumer Healthcare's PE Ratio without NRI falls into.
Prestige Consumer Healthcare EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.67
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prestige Consumer Healthcare (PBH) has a EPS without NRI of $3.67 as of Jun. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Prestige Consumer Healthcare and its competitors. According to the industry distribution chart, Prestige Consumer Healthcare ranks #486 out of 785 companies in the Drug Manufacturers industry, placing it in the top 61.9%.
Is Prestige Consumer Healthcare's EPS without NRI too high?
Prestige Consumer Healthcare's current EPS without NRI is $3.67. The Drug Manufacturers industry median EPS without NRI is 9.70. Prestige Consumer Healthcare's value of $3.67 is 62.2% below this industry median. Based on the distribution chart, Prestige Consumer Healthcare ranks #486 out of 785 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Prestige Consumer Healthcare has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prestige Consumer Healthcare's EPS without NRI compare to BCRX and AMLX?
According to the Drug Manufacturers industry distribution chart, Prestige Consumer Healthcare ranks #486 out of 785 companies for EPS without NRI. This places Prestige Consumer Healthcare in the lower half of its industry. The industry median EPS without NRI is 9.70. Prestige Consumer Healthcare's value of $3.67 is 62.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prestige Consumer Healthcare's current EPS without NRI of $3.67 is 62.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Prestige Consumer Healthcare and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prestige Consumer Healthcare's current EPS without NRI is $3.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prestige Consumer Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Prestige Consumer Healthcare (PBH) is currently considered Modestly Undervalued. The stock's GF Value™ is $70.51, compared to a current price of $50.52 — trading 28.4% below its estimated fair value. The current EPS without NRI is $3.67 and 62.2% below the Drug Manufacturers industry median of 9.70. Prestige Consumer Healthcare's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Prestige Consumer Healthcare (PBH), the current EPS without NRI is $3.67 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prestige Consumer Healthcare (PBH) Overvalued in 2026?
Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued.
The current stock price of $50.52 is trading 28.4% below its estimated GF Value™ of $70.51.
GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.
Key valuation signals for PBH:
EPS without NRI: $3.67
GF Value™: $70.51 vs. price of $50.52 (28.4% below fair value)
Industry Position: 62.2% below the Drug Manufacturers median (#486 of 785)
No single metric tells the full story. See the PBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
69GF Score
Get the complete analysis for PBH
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBH has been successfully added to your 
